Zoster
Conditions
Interventions
Live attenuated varicella vaccine (0.5ml SC.) is administered once to allogeneic HSCT patients without active chronic GVHD or ongoing immunosuppressive therapy at 24 months after HSCT. We recommend co
Sponsors
Division of Hematology, Saitama Medical Center, Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) More than 2 years has passed since allogeneic HSCT 2) Patients without active chronic GVHD or ongoing immunosuppressive therapy 3) ECOG performance status being 0-2 4) The agreement in the document obtained from the person himself about participation in this study (Parental consent is required if patients are < 20 yaers old.)
Exclusion criteria
Exclusion criteria: 1) Patients who have a serious active infection 2) Patients who have a high fever above 37.5 degrees when they receive vaccination 3) Patients who have severe acute illness 4) Patients who experienced an anaphylactic shock due to vaccinations 5) Patients who are or may be pregnant 6) Patients with serious mental disorder 7) Patients who developed VZV disease after allogeneic HSCT 8) Patients with VZV-seronegative before allogeneic HSCT 9) Patients who received inactivated vaccine within 1 week or other live attenuated vaccine within 4 weeks 10) Patients who received transfusions or gamma globulin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of VZV disease | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Adverse effect of vaccine 2)VZV antibody titer before and after vaccination 3)VZV specific CTL before and after vaccinations 4)Factors influencing VZV antibody titer and VZV specific CTL | — |
Countries
Japan
Contacts
Public ContactKoji Kawamura
Saitama Medical Center, Jichi Medical University Division of Hematology
Outcome results
None listed